论文部分内容阅读
胃内膨胀剂型制剂是指通过体积膨胀,使制剂不能通过胃幽门而停留在胃内,从而延长在胃内的滞留时间,增加药物在胃内吸收的制剂。随着药物的释放,制剂通过不断溶蚀而体积变小最后排出胃。胃内膨胀型制剂属于胃内滞留制剂的一种,此类制剂符合缓控释制剂的要求,增加药物在胃部的吸收,提高生物利用度。文中根据胃内膨胀型制剂的研究概况、制剂特点、释药原理和体内评价等方面进行综述,对胃内滞留制剂方面的研究提供参考。
Gastric intrathecal intrathecal dosage form refers to the volume expansion, so that the formulation can not pass through the stomach pylorus and stay in the stomach, thereby prolonging the residence time in the stomach, increase the absorption of drugs in the stomach preparations. As the drug is released, the formulation becomes less and eventually exits the stomach by constant dissolution. Intragastric intrathecal formulations belong to a kind of retention of the stomach, such preparations meet the requirements of controlled release formulations, increase the absorption of drugs in the stomach, improve bioavailability. In this paper, based on the research status of intrathecal intrathecal intrathecal intrathecal formulation, the characteristics of the preparation, the principle of drug release and the evaluation in vivo, the research on the gastric residual preparation is provided as a reference.